Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Most of the focus in generative AI has been on text-based interfaces used to generate text, images, and more. The next wave appears to be voice, and it’s rolling in fast. In the latest ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based ...

This profile has not been claimed by the company. See reviews below to learn more or submit your own review. How do I know I can trust these reviews about The Standard Insurance Company?

2-Year U.S. Treasury Note Continuous Contract $103.535 0.047 0.05% 5-Year U.S. Treasury Note Continuous Contract $108.070 0.148 0.14% 10-Year U.S. Treasury Note Continuous Contract $111.297 0.297 ...